SNS-595 and methods of using the same

Abstract

The present invention relates to SNS-595 and methods of treating cancer using the same.

1 . A method for treating cancer comprising administering to a patient a dose of 10 mg/m 2 -100 mg/m 2  of SNS-595.  
     
     
         2 . The method of  claim 1  wherein the dose is 15 mg/m 2 -80 mg/m 2 .  
     
     
         3 . The method of  claim 1  wherein the cancer being treated is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, and uterine cancer.  
     
     
         4 . The method of  claim 1  additionally comprising administering to a patient a therapeutically effective dose of a supportive care agent.  
     
     
         5 . The method of  claim 4  wherein the supportive care agent is an antiemetic.  
     
     
         6 . The method of  claim 4  wherein the supportive care agent is a hematopoietic agent.  
     
     
         7 . A method of treating a solid tumor comprising: 
 i) administering a dose of 10 mg/m 2 -100 mg/m 2  of SNS-595 to a patient;    ii) waiting a period of at least six days where the subject is not administered any SNS-595;    iii) administering another dose of 10 mg/m 2 -100 mg/m 2  of SNS-595 to the patient; and,    iv) repeating steps ii)-iii) a plurality of times.    
     
     
         8 . A method of treating a solid tumor comprising administering a dose of 15 mg/m 2 -40 mg/m 2  of SNS-595 to a patient once a week wherein the one-week period comprises a treatment cycle and the treatment cycle is repeated at least twice.  
     
     
         9 . A method of treating a solid tumor comprising administering a dose of 35 mg/m 2 -80 mg/m 2  of SNS-595 to a patient once in a three week period wherein the three week period comprises a treatment cycle and the treatment cycle is repeated at least twice.  
     
     
         10 . The method of  claim 9  wherein the patient is a heavily pretreated patient and the dose is 35 mg/m 2 -60 mg/m 2 .  
     
     
         11 . The method of  claim 9  wherein the patient is a heavily pretreated patient and the dose is 40 mg/m 2 -50 mg/m 2 .  
     
     
         12 . The method of  claim 9  wherein the patient is a heavily pretreated patient and the dose is 45 mg/m 2 -50 mg/m 2 .  
     
     
         13 . The method of  claim 9  wherein the patient is a minimally pretreated patient and the dose is 45 mg/m 2 -80 mg/m 2 .  
     
     
         14 . The method of  claim 9  wherein the patient is a minimally pretreated patient and the dose is 50 mg/m 2 -75 mg/m 2 .  
     
     
         15 . The method of  claim 9  wherein the patient is a minimally pretreated patient and the dose is 55 mg/m 2 -65 mg/m 2 .  
     
     
         16 . A method of treating a hematologic cancer comprising: 
 i) administering a dose of 10 mg/m 2 -50 mg/m 2  of SNS-595 to a patient;    ii) waiting a period of at least two days where the subject is not administered any SNS-595;    iii) administering another dose of 10 mg/m 2 -50 mg/m 2  of SNS-595 to the patient; and,    iv) repeating steps ii)-iii) a plurality of times.    
     
     
         17 . The method of  claim 16  wherein the dose 20 mg/m 2 -40 mg/m 2  and the waiting period is six days.  
     
     
         18 . The method of  claim 16  wherein the dose is 10 mg/m 2 -20 mg/m 2  and the waiting period is two or three days.  
     
     
         19 . A method comprising a cycle wherein the cycle comprises administering a dose of SNS-595 to a subject once a week for three weeks followed by a period of at least two weeks where no SNS-595 is administered to said subject and wherein the cycle is repeated a plurality of times.  
     
     
         20 . The method of  claim 19  wherein the dose is 15 mg/m 2 -40 mg/m 2 .  
     
     
         21 . A method for treating cancer comprising administering to a patient a dose of 10 mg/m 2 -100 mg/m 2  of SNS-595 and administering a patient a therapeutically effective dose of a hematopoietic agent.  
     
     
         22 . The method of  claim 21  wherein the hematopoietic agent is G-CSF.  
     
     
         23 . The method of  claim 21  wherein the hematopoietic agent is GM-CSF.  
     
     
         24 . The method of  claim 21  wherein the hematopoietic agent is erythropoietin.  
     
     
         25 . The method of  claim 21  wherein the hematopoietic agent is erythropoiesis stimulating protein.